Drug Trial Radar · NCT06090266
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Oct 24, 2023
Primary completion
Aug 1, 2026
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- OncoResponse, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Conditions
- Cancer
- Tumor, Solid
- Malignant Neoplasm
- Metastatic Cancer
- Advanced Solid Tumor
- Cutaneous Melanoma
- Non-small Cell Lung Cancer
Interventions
OR502Drug
IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
CemiplimabDrug
IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting ToxicityTime frame: First 21 days of treatment.
- Adverse Events and Serious Adverse EventsTime frame: Screening to 90 days from last dose.
- Vital SignsTime frame: Screening to 90 days from last dose.
- Recommended Dose and Regimen (mono and combination therapy)Time frame: Screening to 90 days from last dose.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
NEXT Austin
Austin, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.